FDA SHOULD ENCOURAGE COMPANY-SPONSORED POST HOC EXPLORATORY ANALYSES -- GEORGETOWN's PECK; AGENCY STILL NEEDS TO DEFINE "SUBSTANTIAL EVIDENCE"
Executive Summary
FDA should encourage sponsors to conduct post hoc analyses of efficacy data to generate hypotheses for future research, Georgetown Center for Drug Development Science Director Carl Peck, MD, suggested in May 30 comments.